Newsroom | 4926 results

BUENOS AIRES Y SAN PABLO--(BUSINESS WIRE)--Klick Health recibió 12 galardones este año en el festival El Ojo de Iberoamérica en Buenos Aires, incluido el Gran Premio a la Innovación y seis premios de oro. Dos campañas de Klick, además, clasificaron entre las "Mejores ideas de América". “Este reconocimiento de parte de El Ojo es un testimonio increíble de nuestros equipos globales”, afirmó Rich Levy, CCO. “La pasión, el talento y el empuje incansable siguen impulsando nuestro ritmo de crecimient...

BUENOS AIRES E SÃO PAULO--(BUSINESS WIRE)--A Klick Health ganhou 12 prêmios no Festival El Ojo de Iberoamérica deste ano, em Buenos Aires, incluindo o Grande Prêmio de Inovação e seis prêmios Gold. Duas campanhas da Klick também foram reconhecidas na lista das "Melhores Ideias da América" do festival. "Este reconhecimento do El Ojo é uma prova do trabalho incrível de nossas equipes internacionais", disse Rich Levy, CCO. "A paixão, a capacidade e a dedicação incansável delas continuam impulsiona...

BUENOS AIRES & SÃO PAULO--(BUSINESS WIRE)--Klick Health picked up 12 awards at this year’s El Ojo de Iberoamérica Festival in Buenos Aires, including the Innovation Grand Prix and six Gold. Two Klick campaigns also ranked in the festival’s ‘America’s Best Ideas.’ “This recognition from El Ojo is an incredible testament to our global teams,” said CCO Rich Levy. “Their passion, craft, and relentless drive continue to fuel our record-breaking momentum across the region, and it’s inspiring to see t...

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health is making healthcare more intuitive and personalized by using technology to simplify access and build trust among health plan members....

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts. During the event, Insulet’s executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automa...

TOULOUSE, France & FULLERTON, Californie & LISSES, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société de biotechnologie de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes basées sur la seule apolipoprotéine apoA- I recombinante au monde, et SEBIA, acteur mondial du diagnostic biologique spécialisé, annoncent aujourd’hui un partenariat stratégique exclusif mondial dans le sepsis. De nouveaux tests de...

TOULOUSE, France & FULLERTON, Calif. & LISSES, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, and SEBIA, a global player in specialized biological diagnostics, today announced an exclusive global strategic partnership in sepsis. New tests for early diagnosis and monitoring of sepsis treatme...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced the publication of its new issue brief, Senior Food Insecurity in Kentucky: A Growing Public Health Challenge. The brief examines the complex web of challenges the state’s older adults face in accessing nutritious foods and offers a call to action with recommended investments that can help overcome those barriers. Kentucky ranks 46th among all states in overall se...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...